Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020

Mallet, Vincent; Beeker, Nathanaël; Bouam, Samir; Fontaine, Hélène; Corouge, Marion; Pichard, Anaïs Vallet; Hollande, Clémence; Mehiri, Loriane Lair; Sogni, Philippe; Pol, Stanislas

doi:10.1016/j.jhep.2021.04.052

Cited by 57 publications

(67 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mallet et al have reported the outcomes of hospitalised COVID-19 from the French National Hospital Discharge database including 3207 patients with concomitant cirrhosis. 15 Comparing cirrhotic patients to all noncirrhotic patients produced a mortality OR of 1.73 (1.59-1.88) which is in line with our findings. Adjusted OR for 30-day mortality in compensated cirrhosis (0.71; 0.63-0.80) and decompensated cirrhosis (2.21; 1.94-2.51) were provided, highlighting the importance of delineating cirrhosis severity when prognosticating outcome.…”

Section: Discussionsupporting

confidence: 91%

“…Adjusted OR for 30-day mortality in compensated cirrhosis (0.71; 0.63-0.80) and decompensated cirrhosis (2.21; 1.94-2.51) were provided, highlighting the importance of delineating cirrhosis severity when prognosticating outcome. 15 Mendizabal et al have published an update from their prospective study on hospitalised patients with COVID-19, which was already included in this systematic review. 16 This update provided an adjusted OR 3.1 (1.9-4.8) for patients with cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies

Middleton

Hsu

Lythgoe

2021

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundCOVID-19 continues to pose a significant healthcare challenge throughout the world. Comorbidities including diabetes and hypertension are associated with a significantly higher mortality risk. However, the effect of cirrhosis on COVID-19 outcomes has yet to be systematically assessed.ObjectivesTo assess the reported clinical outcomes of patients with cirrhosis who develop COVID-19 infection.Design/MethodPubMed and EMBASE databases were searched for studies included up to 3 February 2021. All English language primary research articles that reported clinical outcomes in patients with cirrhosis and COVID-19 were included. The study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The risk of bias was assessed using the Quality In Prognostic Score (QUIPS) risk-of-bias assessment instrument for prognostic factor studies template. Meta-analysis was performed using Cochrane RevMan V.5.4 software using a random effects model.Results63 studies were identified reporting clinical outcomes in patients with cirrhosis and concomitant COVID-19. Meta-analysis of cohort studies which report a non-cirrhotic comparator yielded a pooled mortality OR of 2.48 (95% CI: 2.02 to 3.04). Analysis of a subgroup of studies reporting OR for mortality in hospitalised patients adjusted for significant confounders found a pooled adjusted OR 1.81 (CI: 1.36 to 2.42).ConclusionCirrhosis is associated with an increased risk of all-cause mortality in COVID-19 infection compared to non-cirrhotic patients. Patients with cirrhosis should be considered for targeted public health interventions to prevent COVID-19 infection, such as shielding and prioritisation of vaccination.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies

Middleton

Hsu

Lythgoe

2021

BMJ Open Gastroenterol

View full text Add to dashboard Cite

show abstract

“…2 Large registries and data from individual centers suggest that the presence of chronic liver disease (CLD) is associated with poor outcomes, and the risk of mortality is close to 30%-40%. [3][4][5] Among those with CLD, mortality is higher in cirrhotics as compared to non-cirrhotics. [3][4][5] The data available on the influence of COVID-19 in patients with CLD has a few limitations.…”

Section: Introductionmentioning

confidence: 99%

“…[3][4][5] Among those with CLD, mortality is higher in cirrhotics as compared to non-cirrhotics. [3][4][5] The data available on the influence of COVID-19 in patients with CLD has a few limitations. First, the data are controversial about the outcome following COVID-19 infection in patients with CLD.…”

Section: Introductionmentioning

confidence: 99%

Predictors of in-hospital Outcomes in Patients With Cirrhosis and Coronavirus Disease-2019

Elhence

Vaishnav

Biswas

et al. 2022

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…As per our inclusion criteria, all cohort studies were based in Europe and included 23 studies from Spain (14, 16, 17, 22, 28, 29, 32, 33, 35, 50, 54, 57-59, 64, 67, 70, 80, 89, 92, 96, 97, 101), 22 studies from Italy (13,19,21,23,25,30,38,39,45,47,48,55,56,61,62,68,71,77,79,90,91,93), 15 studies from France (20,24,27,31,40,41,43,53,60,63,65,74,76,86,99), ten studies from the UK (26,34,44,49,52,66,72,75,87,98), four included patients from more than one country (69,…”

Section: Resultsmentioning

confidence: 99%

Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe

Vardavas

Mathioudakis

Nikitara

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: As mortality from COVID-19 is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations. Methods: We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to SARS-CoV-2, including death, hospitalisation, Intensive Care Unit (ICU) admission, and mechanical ventilation within three separate settings (community, hospital and ICU). Cohort studies that reported at least age and gender-adjusted data from Europe were identified through a search of peer-reviewed articles published until 11th June 2021 in Ovid Medline and Embase. Results are presented as Odds Ratios (ORs) with 95% confidence intervals (95%C.I.) and absolute risk differences (RD) in deaths per 1,000 COVID-19 patients. Findings: We included 88 cohort studies with age/gender adjusted data from 6,653,207 SARS-CoV-2 patients from Europe. Hospital-based mortality was associated with high and moderate certainty evidence for solid organ tumours, diabetes mellitus, renal disease, arrhythmia, ischemic heart disease, liver disease, and obesity, while a higher risk, albeit with low certainty, was noted for chronic obstructive pulmonary disease and heart failure. Community-based mortality was associated with a history of heart failure, stroke, diabetes, and end-stage renal disease. Evidence of high/moderate certainty revealed a strong association between hospitalisation for COVID-19 and solid organ transplant recipients, sleep apnoea, diabetes, stroke, and liver disease. Interpretation: The results confirmed the strong association between specific prognostic factors and mortality and hospital admission. Prioritisation of booster vaccinations and the implementation of non-pharmaceutical protective measures for these populations may contribute to a reduction in COVID-19 mortality, ICU and hospital admissions. Funding: European Centre for Disease Prevention and Control (ECDC) under specific contract No. 10 ECD.11843 within Framework contract ECDC/2019/001 Lot 1B.

show abstract

Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020

Cited by 57 publications

References 28 publications

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies

Predictors of in-hospital Outcomes in Patients With Cirrhosis and Coronavirus Disease-2019

Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe

Contact Info

Product

Resources

About